Core Viewpoint - The company has entered into an investment agreement to acquire additional equity in Yinghe Medical Technology, recognizing the rapid growth potential in the medical imaging AI sector and the increasing demand for precise and efficient imaging diagnostics [1][2][3] Group 1: Investment Details - The company will invest nearly 100 million RMB to subscribe to the new registered capital of Yinghe Medical Technology, which will increase its total equity stake in the company [1] - This investment is part of the company's strategy to enhance its presence in the medical imaging AI sector, aligning with its long-term development plans [2] Group 2: Strategic Importance - The investment is expected to activate a "twin incubation" development mechanism, leveraging the company's quality data resources and Yinghe's AI technology to create a mutually beneficial growth environment [2] - By enhancing its industrial chain layout through this investment, the company aims to transition towards a data-driven service model, improving its core competitive strength in the industry [2] Group 3: Market Positioning - The investment will significantly improve the diagnostic accuracy and efficiency of the company's imaging centers and partner medical institutions, better meeting clinical needs [2] - This strategic move is anticipated to strengthen the company's position in the rapidly growing imaging AI field, allowing it to seize industry development opportunities and achieve sustained business growth [3]

Core Viewpoint - The company has signed a capital increase agreement with Shanghai Yinghe Medical Technology Co., Ltd., investing nearly 100 million RMB to enhance its stake, reflecting a strategic move to strengthen its position in the rapidly growing medical imaging AI sector [1][2]. Group 1: Investment and Strategic Importance - The investment is part of the company's strategy to implement a three-in-one model of medical imaging AI, which includes medical imaging data, AI foundational models, and imaging center scenarios [2]. - This capital connection is expected to activate a "twin incubation" development mechanism, leveraging the company's accumulated quality data resources and Yinghe Medical's AI technology to create a mutually beneficial development cycle [2][3]. Group 2: Market Position and Competitive Advantage - The investment will enhance the company's industrial chain layout, improve service quality, and strengthen its competitive position in the fast-growing imaging AI field [2][3]. - By utilizing Yinghe Medical's technological advantages, the company aims to transition towards a data-driven service model, thereby increasing its core competitiveness in the industry [2]. - The anticipated outcome of this investment is to solidify the company's leadership position in China's medical imaging AI sector through the construction of a comprehensive "data + algorithm + scenario" closed-loop system [3].

Core Viewpoint - The company has entered into a capital increase agreement with Shanghai Yinghe Medical Technology Co., Ltd., investing nearly 100 million RMB to enhance its stake, reflecting a strategic move to strengthen its position in the rapidly growing medical imaging AI sector [1][2]. Group 1 - The investment aligns with the company's strategy of integrating medical imaging data, AI models, and imaging center scenarios, enhancing its long-term development in the medical imaging field [2]. - The partnership with Yinghe Medical will activate a "twin incubation" mechanism, leveraging the company's quality data resources and Yinghe's AI technology to create a beneficial interaction between information, data, and AI capabilities [2]. - The investment is expected to improve the company's competitive position in the fast-growing imaging AI market, enabling sustained business growth [2][3]. Group 2 - The investment will enhance the company's layout in the medical imaging industry chain, improving the precision and efficiency of imaging diagnostic services [3]. - By utilizing Yinghe's technological advantages, the company aims to transition towards a data-driven service model, thereby increasing its core competitiveness in the industry [2][3]. - The establishment of a "data + algorithm + scenario" closed-loop system will solidify the company's leadership position in China's medical imaging AI sector [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2522） 自願公告 增資於一家醫學影像人工智能公司 本公告由江西一脈陽光集團股份有限公司（「本公司」或「一脈陽光」），連同其附屬 公司統稱（「本集團」）董事（「董事」）會（「董事會」）自願作出。 董事會欣然宣佈，於2025年10月29日（「簽署日」），本公司與上海影禾醫脈智能科 技有限公司（「影禾醫脈」）及其相關各方訂立《增資認購協議》（「協議」）。據此， 本公司以總代價近億元人民幣認購影禾醫脈的新增註冊資本。本次交易完成後， 本公司於影禾醫脈的持股總權益將進一步提升。 董事會認為，醫學影像人工智能作為醫療科技領域未來的核心發展方向，正迎來 市場需求快速釋放的黃金階段。隨著醫療數字化轉型加速，臨床對精準化、高效 化影像診斷的需求日益迫切，這一領域的市場空間將 ...